Knight Reports First Quarter 2017 Results
MONTREAL, QUEBEC–(Marketwired – May 11, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its first quarter ended March 31, 2017. All dollar amounts are in thousands except for per share amounts. All currencies are Canadian unless otherwise specified. “This quarter marked a […]
Knight Therapeutics Inc. announces voting results from the Annual Meeting
MONTREAL, QUEBEC–(Marketwired – May 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Corporation”) announced today the voting results from the Annual Meeting of the Shareholders held in Montréal, Québec (“Meeting”). Election of Directors Each director nominee listed in the Management Information Circular dated March 21, 2017 (“Circular”) was elected as Director of the […]
Notice of Knight Therapeutics’ First Quarter 2017 Results Conference Call
MONTREAL, QUEBEC–(Marketwired – May 4, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its first quarter 2017 financial results on Thursday, May 11, 2017 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST). Knight cordially invites all interested parties […]
Knight to Present at the 2017 Bloom Burton & Co. Healthcare Investor Conference in Toronto
MONTREAL, QUEBEC–(Marketwired – April 25, 2017) – Knight Therapeutics Inc. (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that Samira Sakhia, President, is scheduled to present a corporate update at the Bloom Burton & Co. Healthcare Investor Conference on Monday, May 1, 2017 at 11:30am ET at the Sheraton Centre Toronto Hotel. A copy […]
Knight Rewarded for Doing Pro Bono
MONTREAL, QUEBEC–(Marketwired – March 28, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has assigned its secured loan issued to Pro Bono Bio PLC (“Pro Bono Bio”) and has received full repayment of the balance. Knight generated US$3.3 million from interest and fees from the loan […]
Knight Reports Fourth Quarter and Year-Ended December 31, 2016 Results
MONTREAL, QUÉBEC–(Marketwired – March 16, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2016. All dollar amounts are in thousands except for per share amounts. All currencies are Canadian unless otherwise specified. “In 2016, we […]
Knight Therapeutics Announces the Canadian commercialization of MOVANTIK®
MONTREAL, QUEBEC–(Marketwired – March 13, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today the commercial relaunch of MOVANTIK, indicated for the treatment of opioid-induced constipation (“OIC”) in adult patients with non-cancer pain who have had an inadequate response to laxative(s)1. Opioid binding to receptors within the gastrointestinal tract […]
Notice of Knight Therapeutics’ Fourth Quarter and Year Ended December 31, 2016 Results Conference Call
MONTREAL, QUÉBEC–(Marketwired – March 10, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, will release its fourth quarter and year ended December 31, 2016 financial results on Thursday, March 16, 2017 prior to the market opening. Following the release, Knight will hold a conference call at 8:30 a.m. (EST). Knight […]
Knight Therapeutics Inc. Announces Board Change
MONTREAL, QUÉBEC–(Marketwired – Feb. 23, 2017) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”) announced today (i) the resignation of Ed Schutter and (ii) the appointment Dr. Sarit Assouline to Knight’s Board of Directors. “I thank Ed for his meaningful contributions to Knight since joining in early 2015,” said Jonathan Ross Goodman, CEO of Knight. “In his […]
Knight Plants Small Seed Position In Protalix
MONTREAL, QUEBEC–(Marketwired – Jan. 26, 2017) – Knight Therapeutics Inc. (“Knight”) (TSX:GUD), a leading Canadian specialty pharmaceutical company, announced today that it has acquired 6,200,000 common shares (“Shares”) of Israeli based Protalix BioTherapeutics, Inc. (“Protalix”) at an average price of US$0.57 per share. Knight now owns approximately 5% of the outstanding common shares of Protalix. […]
